TransMedics Group (NASDAQ:TMDX) Price Target Raised to $127.00 at JPMorgan Chase & Co.

TransMedics Group (NASDAQ:TMDX) had its price objective upped by JPMorgan Chase & Co. from $105.00 to $127.00 in a research note issued to investors on Wednesday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Oppenheimer raised their price objective on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an outperform rating in a research note on Wednesday. Piper Sandler reissued an overweight rating and issued a $120.00 price target (up from $95.00) on shares of TransMedics Group in a report on Wednesday. Finally, Morgan Stanley boosted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an equal weight rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $119.00.

TransMedics Group Trading Up 2.9 %

TransMedics Group stock opened at $127.99 on Wednesday. The firm has a fifty day moving average price of $85.54 and a two-hundred day moving average price of $77.08. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $129.66. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.40. The business had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $83.78 million. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The firm’s revenue was up 132.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.08) EPS. On average, research analysts anticipate that TransMedics Group will post 0.62 EPS for the current year.

Insider Activity

In related news, Director Edward M. Basile sold 7,157 shares of the stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total value of $618,221.66. Following the completion of the transaction, the director now owns 8,350 shares of the company’s stock, valued at $721,273. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Edward M. Basile sold 7,157 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total value of $618,221.66. Following the sale, the director now owns 8,350 shares in the company, valued at approximately $721,273. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 736 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total transaction of $66,306.24. Following the sale, the insider now owns 14,375 shares of the company’s stock, valued at approximately $1,295,043.75. The disclosure for this sale can be found here. In the last three months, insiders have sold 236,378 shares of company stock worth $23,633,449. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. J.W. Cole Advisors Inc. bought a new position in TransMedics Group in the 3rd quarter valued at $929,000. Bank of New York Mellon Corp raised its holdings in shares of TransMedics Group by 91.4% in the third quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock valued at $41,615,000 after buying an additional 363,012 shares during the last quarter. Shariaportfolio Inc. acquired a new position in TransMedics Group during the 3rd quarter worth about $470,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in TransMedics Group by 12.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,913 shares of the company’s stock worth $378,000 after acquiring an additional 763 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in TransMedics Group by 12.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,940 shares of the company’s stock valued at $818,000 after acquiring an additional 1,700 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.